Wedbush Maintains Outperform on SpringWorks Therapeutics, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten maintains an Outperform rating on SpringWorks Therapeutics (NASDAQ:SWTX) and raises the price target from $60 to $70.
February 26, 2024 | 2:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has maintained an Outperform rating on SpringWorks Therapeutics and increased the price target from $60 to $70.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100